EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
Status:
Completed
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
This study is a regulatory post-marketing surveillance in Japan, and it is a local
prospective and observational study of patients who have received EYLEA for Age-Related
Macular Degeneration (AMD).
The objective of this study is to assess safety and effectiveness of EYLEA using in real
clinical practice.
A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational
period. An annual follow-up survey will be conducted for 5 years at the longest after
standard observational period.